Cybin to host conference call and webcast to provide program update for cyb003

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that it will host a conference call and webcast at 8:30 a.m. et on wednesday, march 13, 2024. the company will provide a program update on cyb003, its proprietary deuterated psilocybin analog in development.
CYBN Ratings Summary
CYBN Quant Ranking